Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Routine Versus Selective Protamine Administration After TAVI
NCT05774691Phase 4Completed
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of protamine in aortic valve stenosis (2 arms). Primary endpoint: Composite of all-cause mortality or type 1-4 bleeding at 30 days. Started Nov 2023; status: completed.
02
Drugs
protamine
03
Conditions
aortic valve stenosis
Beyond the preview
Go deeper on NCT05774691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774691.